Surmodics (SRDX)
(Delayed Data from NSDQ)
$41.55 USD
-0.26 (-0.62%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $41.50 -0.05 (-0.12%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Surmodics, Inc. [SRDX]
Reports for Purchase
Showing records 341 - 360 ( 418 total )
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Q3 results slightly below estimates, EPS guidance range raised, to STRONG BUY
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Q2 FY2013 results slightly below estimates, guidance reaffirmed, BUY
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Surmodics, Inc.
Industry: Medical - Products
Notes from management travel, company visit, raising price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Q1 FY2013 results modestly ahead, guidance raised, raising price target to $27.50
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Q4 2012 results modestly ahead, 2013 guidance inline, raising price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
SRDX Q3 2012 results beat handily, tender offer announced, raising rating and PT
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
Company: Surmodics, Inc.
Industry: Medical - Products
SRDX Q2 12 revenue somewhat light, but operating margin well above expectations
Provider: FELTL & COMPANY
Analyst: ANDBERG E